Cargando…

Switching to a 'nuke-sparing' raltegravir/atazanavir combination: an individualised approach

Detalles Bibliográficos
Autores principales:	Grant, A, Kamuntu, Y, Read, P, Kulasegaram, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113035/ http://dx.doi.org/10.1186/1758-2652-13-S4-P33

Ejemplares similares

Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study
por: Le Moal, G, et al.
Publicado: (2010)

Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study
por: Carrero-Gras, Ana, et al.
Publicado: (2014)

High levels of polymorphisms related to raltegravir resistance among raltegravir-naïve individuals in Brazil
por: Pena, N Mantovani, et al.
Publicado: (2010)

Therapeutic drug monitoring (TDM) of atazanavir in pregnancy
por: Else, LJ, et al.
Publicado: (2010)

Switch to once or twice daily unboosted atazanavir in a cohort of stable HIV patients: strong differences in drug exposure and virological outcome
por: Baudry, T, et al.
Publicado: (2010)

Assessing the risk of birth defects associated with atazanavir exposure in pregnancy
por: Esker, S, et al.
Publicado: (2010)

Salvage therapy with raltegravir in a 3-month-old infant
por: Brolund, AB, et al.
Publicado: (2010)

Digital Compositing with Nuke
por: Lanier, Lee
Publicado: (2012)

PHP-Nuke garage
por: Jones, Don
Publicado: (2005)

Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study
por: van Lunzen, Jan, et al.
Publicado: (2016)

Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice
por: Gantner, Pierre, et al.
Publicado: (2016)

Minding the gap between theory and clinical practice: an individualised approach to the management of feline diabetes mellitus
por: Lewitt, Moira S, et al.
Publicado: (2015)

Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting
por: Bonora, S, et al.
Publicado: (2010)

Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice
por: Llibre, JM, et al.
Publicado: (2010)

Safety and efficacy of ombitasvir – 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens
por: Eron, Joseph J, et al.
Publicado: (2014)

Warfare: NRDC Knocks Nukes
por: Chepesiuk, Ron
Publicado: (2004)

PostNuke content management
por: Hatch, Kevin
Publicado: (2005)

DotNetNuke for dummies
por: Young, Lorraine
Publicado: (2007)

Use of once-daily raltegravir-based HAART in HIV-infected injection drug users
por: Tossonian, HK, et al.
Publicado: (2010)

Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
por: Overton, T, et al.
Publicado: (2010)

Nevirapine (NVP) vs ritonavir-boosted atazanavir (ATV/r) combined with tenofovir/emtricitabine (TDF/FTC) in first-line therapy: NEWART 48-week data
por: DeJesus, E, et al.
Publicado: (2010)

Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced HIV patients
por: Jansen, K, et al.
Publicado: (2010)

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
por: Broder, MS, et al.
Publicado: (2010)

SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV-infected patients
por: Siccardi, M, et al.
Publicado: (2010)

Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature
por: Ceccarelli, Giancarlo, et al.
Publicado: (2011)

DotNetNuke 54 Cookbook
por: Murphy, John K
Publicado: (2010)

Nuke physicist with Qaeda links arrested
Publicado: (2009)

Nuke plant scientist on terror rap
Publicado: (2009)

Portuguese cohort: raltegravir with optimized background therapy (OBT) in multiple-experienced HIV1- and HIV2-infected patients
por: Doroana, M, et al.
Publicado: (2010)

Enteral nutrition in adult ICU patients: optimizing the outcome using computer-assisted individualisation of nutritional support
por: Archodovassilis, F, et al.
Publicado: (2004)

Raltegravir-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: implications for clinical practice and patient safety
por: Perry, MEO, et al.
Publicado: (2010)

Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from a multicenter study
por: Madeddu, G, et al.
Publicado: (2010)

High-throughput optical proteomics and breast cancer patient profiling: novel applications to individualise prognosis and treatment
por: Kelleher, MT, et al.
Publicado: (2008)

Resistance after viral failure on atazanavir-containing therapy: multinational clinical cohort (BMS AI424-128 — 'IMPACT') final analysis
por: Zolopa, A, et al.
Publicado: (2010)

Cold war, hot nukes: legacy of an era.
por: Clay, R
Publicado: (2001)

Nuke 101: professional compositing and visual effects
por: Ganbar, Ron
Publicado: (2011)

Professional DotNetNuke Module Programming
por: Sellers, Mitchel, et al.
Publicado: (2009)

Beginning DotNetNuke Skinning and Design
por: Hay, Andrew, et al.
Publicado: (2011)

Nuke 101: professional compositing and visual effects
por: Ganbar, Ron
Publicado: (2014)

Long-term follow-up of HIV-infected patients in salvage therapy with raltegravir plus optimized background regimens: a multicentre Italian experience
por: Landonio, S, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_3su839hfoti3fbarppk0t97115